This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

Margaret Echerd Biography and Net Worth

SVP of Vaxart

Margaret Echerd is Vaxart’s Senior Vice President and Principal Accounting Officer. She is responsible for the Finance, Accounting, Human Resources, Facilities and IT functions of the organization.
Prior to Vaxart, Ms. Echerd was the Controller of Autonomic Technologies, Inc., a medical device company. Ms. Echerd has previously served as Vice President, Corporate Controller of Quotient Technology, Inc., a digital marketing company. Ms. Echerd held various accounting positions at Extreme Networks, Inc., a networking technology company, including Vice President, Corporate Controller, and Chief Accounting Officer. Ms. Echerd who is a certified public accountant in California, received a B.B.A from Texas A&M University and an M.B.A. from Golden Gate University.

What is Margaret Echerd's net worth?: The estimated net worth of Margaret Echerd is at least $234.00 as of September 10th, 2021. Ms. Echerd owns 334 shares of Vaxart stock worth more than $234 as of April 25th. This net worth estimate does not reflect any other assets that Ms. Echerd may own. Learn More about Margaret Echerd's net worth.
How do I contact Margaret Echerd?: The corporate mailing address for Ms. Echerd and other Vaxart executives is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. Vaxart can also be reached via phone at (650) 550-3500 and via email at [email protected]. Learn More on Margaret Echerd's contact information.
Has Margaret Echerd been buying or selling shares of Vaxart?: Margaret Echerd has not been actively trading shares of Vaxart within the last three months. Most recently, Margaret Echerd sold 3,602 shares of the business's stock in a transaction on Tuesday, November 30th. The shares were sold at an average price of $8.00, for a transaction totalling $28,816.00. Learn More on Margaret Echerd's trading history.
Who are Vaxart's active insiders?: Vaxart's insider roster includes Margaret Echerd (SVP), Wouter Latour (Director), and Sean Tucker (SVP). Learn More on Vaxart's active insiders.

Margaret Echerd Insider Trading History at Vaxart

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/30/2021	Sell	3,602	$8.00	$28,816.00
9/10/2021	Sell	1,801	$9.10	$16,389.10	334
7/19/2021	Sell	1,800	$8.00	$14,400.00	333
6/9/2021	Sell	47,555	$8.00	$380,440.00	12,333

Margaret Echerd Buying and Selling Activity at Vaxart

Vaxart Company Overview

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical dysplasia. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Today's Range

Now: $0.70

$0.69

$0.72

50 Day Range

MA: $1.14

$0.75

$1.41

2 Week Range

Now: $0.70

$0.53

$1.59

Volume

564,316 shs

Average Volume

1,944,034 shs

Market Capitalization

$123.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44